Treatment of the refractory schizophrenic patient

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 1, 1998, Pages 13-21

  Daniel, David G ^a   Whitcomb, Stacy R ^a  

^a Clinical Studies Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SERTINDOLE; ZIPRASIDONE;

ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG RESISTANCE; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; VERTIGO;

EID: 0031908148     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Meltzer HY. Cost-effectiveness of clozapine treatment. J Clin Psychiatry Monograph: 1996;14(2):16-17
2. Moller HJ, von Zerssen D. Psychopathometric study of the prognostic significance of psychopathologic findings and premorbid personality for discharge of neuroleptic treated patients with schizophrenic psychoses. Nervenarzt 1985;56:498-505
3. Akbarian S, Bunney WE Jr, Potkin SG, et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993;50:169-177
4. Akbarian S, Vinuela A, Kim JJ, et al. Distorted distribution of nicotinamide adenine dinucleotide phosphate-diaphorase neurons in temporal lobes of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993;50:178-187
5. Altshuler LL, Casanova ME Goldberg TE, et al. The hippocampus and parahippocampus in schizophrenic, suicide, and control brains. Arch Gen Psychiatry 1990;47:1029-1034
6. Benes FM. Evidence for neurodevelopmental disturbances in anterior cingulate cortex of post-mortem schizophrenic brain. Schizophr Res 1991;5: 187-188
7. Suddath RL, Christison GW, Torey EF, et al. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med 1990;322:789-794
8. Daniel DG, Goldberg TE, Gibbons RD, et al. Lack of a bimodal distribution of ventricular size in schizophrenia: a Gaussier mixture analysis of 1056 cases and controls. Biol Psychiatry 1991;30:887-903
9. Umbricht DS, Leiberman Kane JM. The clinical efficacy of clozapine in the treatment of schizophrenia. Rev Contemp Pharmacotherapy 1995;6: 165-186
10. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
11. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist, choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 17; 2:2217-2245
12. Schulz SC, Buckley PF. Treatment resistant schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell Science Ltd; 1995:469-480
13. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991;148:714-726
14. Daniel DG, Linnoilia M, Randolph C, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340-343
15. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265
16. Daniel DG, Randolph C, Jaskiw G, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340-343
17. Soubrie P, Reisine TD, Glowinski J. Functional aspects of serotonin transmission in the basal ganglia: a review and an in vivo approach using the push-pull cannula technique. Neuroscience 1984;13:605-625
18. 2 dopamine receptor blockade. J Pharmacol Exp Ther 1990;253:1162-1170
19. Daniel DG, Weinberger DR, Jones DW, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 1991;11:1907-1917
20. Daniel DG, Berman KF, Weinberger DR. The effect of apomorphine on regional cerebral blood flow in schizophrenia. J Neuropsychiatry Clin Neurosci 1989;1:377-384
21. Golberg TE, Bigelow LB, Weinberger DR, et al. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 1991;148:78-84
22. Darby JK, Pasta DJ, Dabiri L, et al. Haloperidol dose and blood level variability: toxicity and interindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 15;5:334-340
23. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
24. Schooler N, Cain J, Marter J, et al. Efficacy of clozapine versus haloperidol in a long term clinical trial: preliminary findings. In: Abstracts of the 33rd Annual Meeting of American College of Neuropsychopharmacology; Dec 11-16, 1994; San Juan, Puerto Rico. Abstract 223
25. Owen RR, Beake BJ, Marby D, et al. Response to clozapine in chronic psychotic patients. Psychopharmacol Bull 1989;25:253-256
26. Meltzer HJ. Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160(suppl 17):46-53
27. Breier A, Buchanan RW, Irish D, et al. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993;44:1145-1149
28. Clozapine Study Group. The safety and efficacy of clozapine in severe treatment resistant schizophrenic patients in the UK. Br J Psychiatry 1993; 163:150-154
29. Jalenques I, Coudert AJ. A new therapeutic approach to drug-resistant schizophrenic patients: clozapine. Long term prospective study in 16 patients. Acta Psychiatr Belg 1992;92:323-338
30. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-1752
31. Kane J, Schooler N, Marder S. A six month comparison of clozapine and haloperidol. In: Scientific Abstracts of the 35th Annual Meeting of the American College of Neuropsychopharmacology; Dec 9-13, 1996; San Juan, Puerto Rico. Abstract 65
32. Miller DD, Fleming F, Holman TL, et al. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55(9, suppl B):117-121
33. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55(9, suppl B):133-136
34. Lee HS, Kwon KY, Alphs LD, et al. Effect of clozapine on psychogenic polydipsia in chronic schizophrenia [letter]. J Clin Psychopharmacol 1991; 11:222-223
35. Munn NA. Resolution of polydipsia and hyponatremia in schizophrenic patients after clozapine treatment [letter]. J Clin Psychiatry 1993;54: 439-440
36. Henderson DC, Goff DC. Clozapine for polydipsia and hypernatremia in chronic schizophrenia. Biol Psychiatry 1994;36:768-770
37. Leadbetter RA, Shutty MS Jr. Differential effects of neuroleptics and clozapine on polydipsia and intermittent hyponatremia. J Clin Psychiatry 1994; 55:(9, suppl B):110-113
38. Mallya AR, Roos PD, Roebuck-Colgan K. Restraint, seclusion, and clozapine. J Clin Psychiatry 1992;53:395-397
39. Volavka J, Zito JM, Vitrai J, et al. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993;13:287-289
40. Ratey JJ, Leveroni C, Kilmer D, et al. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry 1993; 54:219-223
41. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
42. Owen RR Jr, Beake BJ, Marby D, et al. Response to clozapine in chronic psychotic patients. Psychopharmacol Bull 1989;25:253-256
43. Naber P, Hippius H. The European experience with the use of clozapine. Hosp Community Psychiatry 1990;41:886-890
44. McElroy SL, Dessain EC, Pope HG, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-414
45. Banov MD, Zarate CA Jr, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994;55:295-300
46. Leiberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510
47. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(9, suppl B):102-106
48. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(9, suppl B):102-106
49. Gardner EL, Chen J, Paredes W. Clozapine produces potent antidopaminergic effects anatomically specific to the mesolimbic system. J Clin Psychiatry 1994;55(9, suppl B):15-22
50. Fibiger HC. Neuroanatomical targets of neuroleptic drugs as revealed by Fos immimochemistry. J Clin Psychiatry 1994;55(9, suppl B):33-36
51. Moghaddam B. Preferential activation of cortical dopamine neurotransmission by clozapine: functional significance. J Clin Psychiatry 1994;55(9, suppl B):27-29
52. Dixon AK, Huber C, Lowe DA. Clozapine promotes approach-oriented behavior in male mice. J Clin Psychiatry 1994;55(9, suppl B):4-7
53. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55(9, suppl B):47-52
54. Chouinard G, Vainer JL, Belanger MC, et al. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:1129-1141
55. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
56. Abuzzahab FS, Gillard JM. Clozapine and risperidone in schizophrenia. In: Scientific Abstracts of the 33rd Annual Meeting of the American College of Neuropsychopharmacology; Dec 12-16, 1994; San Juan, Puerto Rico. Abstract 225
57. Roose K, Gelders Y, Heylen S. Risperidone (R64 766) in psychotic patients: a first clinical therapeutic exploration. Acta Psych Belg 1988;88: 233-241
58. Bressa GM, Bersani G, Meco G, et al. One year follow-up study with risperidone in chronic schizophrenia. New Trends in Experimental and Clinical Psychiatry 1991;7(4):169-177
59. Small JG, Miller MJ, Klapper MH, et al. Risperidone versus clozapine in resistant schizophrenia. In: Programs and Abstracts of the 146th Annual Meeting of the American Psychiatric Association; May 27, 1993; San Francisco. Calif. Abstract NR724:241
60. Chouinard G, Vainer JL, Belanger MC, et al. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:1129-1141
61. Kronig MH, Loebel AD, et al. Risperidone in treatment-resistant schizophrenia and schizoaffective patients. In: Syllabus of the APA 46th (1994) Institute of Hospital and Community Psychiatry; Sept 30-Oct 4, 1994; San Diego, Calif. Abstract 72
62. Evans EG. Risperidone in institutionalized psychotic patients unresponsive to conventional antipsychotic agents. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 24, 1995: Miami, Fla. Abstract NR491:187
63. Cavallero R, Colombo C, Smeraldi E. A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Human Psychopharmacology 1995;10:231-243
64. Ibrahim ZY, Buckley PJ, Donenwirth K, et al. Risperidone treatment of schizophrenia in a state hospital. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 23, 1995; Miami, Fla. Abstract NR9:56
65. Lindenmayer J-P, Vital-Herne M, Simon FS, et al. Use of risperidone in neuroleptic refractory schizophrenics in a state psychiatric center. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 23, 1995; Miami, Fla. Abstract NR208:112
66. Raza A, Ettinger T, Snarif ZA, et al. A comparison of the efficacy of clozapine and risperidone in treatment refractory schizophrenia. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 23, 1995; Miami, Fla. Abstract NR228: 117
67. Home RL, Miller F. Outcome in schizophrenic patients switched from clozapine to risperidone. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 24, 1995; Miami, Fla. Abstract NR447:175
68. Tanner TB, Ganguli R, Reddy R, et al. Risperidone for treatment-refractory schizophrenia [letter]. Am J Psychiatry 1995;152:1233
69. Lacey RL, Preskom SH, Jerkovich GS. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics [letter]? Am J Psychiatry 1995;152:1401
70. Bacher NM, Kaup BA. Combining risperidone with standard neuroleptics for refractory schizophrenic patients [letter]. Am J Psych 1996;153:137
71. Bondolfi G, Bauman P, Patris M, et al. A randomized double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 24, 1995; Miami, Fla. Abstract NR485:185
72. Klieser E, Lehmann E, Kinzler E, et al. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995;15(suppl 1):45S-51S
73. Daniel DG, Goldberg TE, Weinberger DR, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996;153:417-419
74. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96
75. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
76. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol: results of the multicenter, international trial. Schizophr Res 1996;18:131
77. Hyttel J, Nielsen JB, Nowak G. The acute effect of sertindole on brain 5-HT-2, D-2, and alpha-1 receptors (ex vivo radioreceptor binding studies). J Neural Transm 1991;89:61-69
78. Van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124:168-175
79. Schulz SC, Mack R, Zborowski J, et al. Efficacy, safety, and dose response of three doses of sertindole in schizophrenia patients. Schizophr Res 1996; 18:133
80. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112:285-292
81. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88, 059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-113
82. Sorensen SM, Kehne JH, Fadayel GM, et al. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putatative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 1993;266:684-691
83. Schmidt CJ, Fadayel GM, Sullivan CK, et al. 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100.907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 1992;223:65-74